ОСОБЕННОСТИ ТЕЧЕНИЯ И ЛЕЧЕНИЕ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА В СОЧЕТАНИИ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. ЛИТЕРАТУРНЫЙ ОБЗОР
Литературный обзор посвящен особенностям течения, выбору лекарственных препаратов для лечения ишемической болезни сердца в сочетании с артериальной гипертензией.
С.М. Исаханова
КГКП «Реабилитационный центр для инвалидов и участников Великой Отечественной войны»
1. Всероссийское научное общество кардиологов (ВНОК). Национальные рекомендации по диагностике и лечению артериальной гипертонии. М 2004.
2. Комитет экспертов ВНОК. Диагностика и лече-ние стабильной стенокардии. Российские рекоменда-ции. Кардиоваскулярная терапия и профилактика (при-ложение) 2004.
3. Сыркин А.Л. Лечение стабильной стенокардии. Consilium medicum. 2000; 2:470–477.
4. ASCOT study investigators, 2005. http://www.ascotstudy.org/home. Htm.
5. Armstrong P.W. Stable ischemic syndromes. In: Textbook of cardiovascular medicine. Ed. E.J. Topol. Phila-delphia PA: Lippincott Williams & Wilkins-Raven 1998;333-364.
6. Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: INSIGHT. Lancet 2000;356:366-372.
7. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high pressure: The JNC 7 report. JAMA 2003; 289:2560–2572.
8. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
9. Dzau V., Bernstein K., Celermaier D. et al. The relevance of tissue angiotensin-converting enzyme: mani-festations in mechanistic and endpoint data. Am J Cardiol 2001;88:Suppl L:L1-L20.
10. Grundy S.M., Cleeman A., Merz C.N.B. Implica-tions of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-239.
11. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
12. Hansson L., Hedner T., Lund-Johansen P. et al. Randomised trial of effects of calcium antagonists com-pared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Dilti-azem (NORDIL) study. Lancet 2000;356:359-365.
13. Hansson L., Lindholm L., Ekbom T. et al. Ran-domised trial of old and new antihypertensive drugs in el-derly patients: cardiovascular morbidity and mortality the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-1756.
14. Julius S., Kjeldsen S.E., Weber M. et al. Out-comes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipin: the VALUE randomised trial. Lancet 2004;363:2021-2031.
15. La Rosa J.C., Grundy S.M., Waters D.D. et al. In-tensive lipid lowering with atorvastatin in patients with sta-ble coronary disease. N Engl J Med 2005;352:1425-1435.
16. Neaton J.D.,Wentworth D. for the Multiple Risk Factor Intervention Trial Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Arch Intern Med 1992;152:56-64.
17. Nissen S.E., Tuscu E.M., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in pa-tients with coronary artery disease and normal blood pres-sure. The CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-2226.
18. PEACE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery dis-ease. N Engl J Med 2004;351:2058-2068.
19. Pepine C., Handberg E.M., Cooper-deHoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-2816.
20. Pitt B., O'Neill B., Feldman R. et al. The Quin-april Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart dis-ease and preserved left ventricular function. Am J Cardiol 2001;87:1058-1063.
21. Rosendorff C. Treatment of hypertension patients with ischemic heart disease. In: Hypertension Primer: The essentials of high blood pressure: basic science, population science, and clinical management. Eds. J.L.Jr. Izzo, H.R. Black. Philadelphia PA: Lippincott Williams & Wilkins 2003;456-459.
22. Sever P.S., Dahlof B., Poulter N.R. et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-1158.
23. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002;288:2981-2997.
Количество просмотров: 217
Библиографическая ссылка
Похожие публикации:
IN-STENT THROMBOSIS AND RESTENOSIS OF THE CORONARY ARTERIES IN PATIENTS WITH CORONARY HEART DISEASE AFTER CORONAVIRUS INFECTION
МЕХАНИКАЛЫҚ САРҒАЮ ОПЕРАЦИЯСЫ КЕЗІНДЕ КОАГУЛОПАТИЯЛЫҚ ҚАН КЕТУДІҢ АЛДЫН АЛУ ӘДІСІ
ОПТИМИЗАЦИЯ РЕЗУЛЬТАТОВ АУТОДЕРМОПЛАСТИКИ ПРИ ЛЕЧЕНИИ ГРАНУЛИРУЮЩИХ ГНОЙНЫХ РАН
BASICS OF REHABILITATION OF CHILDREN AFTER OPERATIONS ON THE COLON AND ANORECTAL AREA
HEALTH INDICATORS OF FIRST-YEAR-OF-LIFE CHILDREN IN THE REPUBLIC OF KAZAKHSTAN FOR 2013-2022